Hemostatic rebalancing agents in hemophilia care.

HEMOPHILIACS; HEMOPHILIA; HEMOPHILIA treatment; BLOOD coagulation factor VIII; RNA interference; MANAGED care programs

The article focuses on three hemostatic rebalancing agents for the treatment of hemophilia that are in the late stages of development. The investigational RNA interference agent called Fitusiran increases the production of thrombin, which helps blood to clot by reducing the synthesis of antithrombin. Marstacimab is a monoclonal antibody that targets tissue factor pathway inhibitor (TFPI). Concizumab is also a subcutaneously administered TFPI-targeting recombinant antibody.